Table 2.
Phase 11/III clinical trials of anti-VEGF tyrosine kinase inhibitors agents in advanced gastric cancer
| Drug | Number of patients | Line | ORR (%) | PFS (months) [HR (95% CI), p value] | OS (months/days) [HR (95% CI), p value] | ||
|---|---|---|---|---|---|---|---|
| Sunitinib | 78 | 2 | 3.9 | 31.28 | 5.81 | ||
| Sorafenib | 44 | 1 | 41 | 5.8 | 13.6 | ||
| Apatinib (850 mg) | 270 | 1 | |||||
| Apatinib group | 180 | 2.84 | 78 | HR 0.44, 95% CI 0.33–0.61 p < 0.0001 |
195 days | HR 0.71, 95% CI 0.54–0.94 p < 0.06 |
|
| Placebo group | 90 | 0.00 | 53 | 140 days | |||
| Trebananib | 171 | 1 | |||||
| Treb (10 mg) | 27 | 4.2 | HR 0.98 95% CI 0.67–1.43 p = 0.92 |
NR | |||
| Treb (3 mg) | 43 | 4.9 | NR | ||||
| Ch + placebo | 35 | 5.2 | NR | ||||
| Regorafenib | 147 | 1 | |||||
| Rego group | 97 | NR | 11.1 | 25 weeks | |||
| Placebo group | 50 | NR | 3.9 | p = 0.0001 | 19.4 weeks | p = 0.11 | |
ORR median overall response rate, TTP median time to progression, PFS median progression-free survival, OS median overall survival, HR hazard ratio, CI confidence interval, Ch chemotherapy, Treb Trebananib, NR not reported